指南与共识肾癌与肾肿瘤

欧洲泌尿外科学会肾细胞癌指南:2022年更新版

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update.
指南 / 共识 · Eur Urol · 2022-03-26

欧洲泌尿外科学会(EAU)肾细胞癌指南专家组基于标准化方法学制定2022年更新版指南,文献检索截止2021年5月28日,覆盖Medline、EMBASE和Cochrane数据库,采用改良GRADE标准进行证据合成,为肾细胞癌管理提供循证推荐。

要点

  • EAU肾细胞癌指南2022年更新版基于系统评价和改良GRADE标准制定。
  • 文献检索截止2021年5月28日,覆盖Medline、EMBASE和Cochrane数据库。
  • 纳入研究多数为回顾性匹配或非匹配队列,转移性肾细胞癌全身治疗除外。

核心结论

  • 2022年肾细胞癌指南由多学科专家组使用最高方法学标准更新,为2022年肾细胞癌管理提供最可靠的当代证据基础。

研究设计与样本

  • 欧洲泌尿外科学会(EAU)肾细胞癌指南专家组制定了基于证据的指南和推荐。
  • 2022年更新进行了新的文献检索,截止日期为2021年5月28日,覆盖Medline、EMBASE和Cochrane数据库。
  • 数据检索聚焦于随机对照试验(RCT)、回顾性或对照比较组研究、系统评价(SR)和Meta分析。
  • 证据合成采用改良GRADE标准,按照所有EAU指南的概述进行。

主要发现

  • 肾细胞癌指南所有章节基于结构化文献评估进行了更新,并制定了临床实践推荐。
  • 纳入研究多数为回顾性匹配或非匹配队列,基于单中心或多中心数据或国家登记数据库。
  • 转移性肾细胞癌的全身治疗例外,有多项大型随机对照试验,因此推荐基于更高证据级别。

局限性

  • 纳入研究多数为回顾性匹配或非匹配队列,基于单中心或多中心数据或国家登记数据库。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The European Association of Urology (EAU) Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of RCC. OBJECTIVE: To present a summary of the 2022 RCC guideline, which is based on a standardised methodology including systematic reviews (SRs) and provides transparent and reliable evidence for the management of RCC. EVIDENCE ACQUISITION: For the 2022 update, a new literature search was carried out with a cutoff date of May 28, 2021, covering the Medline, EMBASE, and Cochrane databases. The data search focused on randomised controlled trials (RCTs) and retrospective or controlled comparator-arm studies, SRs, and meta-analyses. Evidence synthesis was conducted using modified GRADE criteria as outlined for all the EAU guidelines. EVIDENCE SYNTHESIS: All chapters of the RCC guideline were updated on the basis of a structured literature assessment, and clinical practice recommendations were developed. The majority of the studies included were retrospective with matched or unmatched cohorts and were based on single- or multi-institution data or national registries. The exception was systemic treatment of metastatic RCC, for which there are several large RCTs, resulting in recommendations that are based on higher levels of evidence. CONCLUSIONS: The 2022 RCC guidelines have been updated by a multidisciplinary panel of experts using the highest methodological standards. These guidelines provide the most reliable contemporary evidence base for the management of RCC in 2022. PATIENT SUMMARY: The European Association of Urology panel for guidelines on kidney cancer has thoroughly evaluated the research data available to establish up-to-date international standards for the care of patients with kidney cancer.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. 2022. PMID: 35346519. doi:10.1016/j.eururo.2022.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。